SCHEMBL5559525

SCHEMBL5559525

C=C(C(=O)c1ccc(S(=O)(=O)Nc2cc(C)on2)cc1)c1cc(-c2cccs2)c(OC)cc1OCC(CO)CO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.43
POLB P06746 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 3/20 0.42
ALOX12 P18054 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NPC1 O15118 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GAA P10253 1/20 0.40
MEN1 O00255 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 2/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5564202 0.91 HPGD (0.49) HPGDPOLBL3MBTL1KMT2AALOX12
SCHEMBL5564344 0.90 NPC1 (0.45) HPGDPOLBL3MBTL1KMT2AALOX12
SCHEMBL5560084 0.90 HPGD (0.49) HPGDPOLBL3MBTL1KMT2AALOX12
SCHEMBL5559533 0.84 TNFRSF1A (0.45) HPGDPOLBL3MBTL1KMT2AALOX12
SCHEMBL5559531 0.84 TNFRSF1A (0.45) HPGDPOLBL3MBTL1KMT2AALOX12
SCHEMBL6040637 0.84 CA2 (0.41) L3MBTL1KMT2ARXFP1MEN1KDM4E
Hydrochloric Acid SCHEMBL5566518 0.83 FLT3 (0.40) HPGDPOLBL3MBTL1KMT2AALOX12
SCHEMBL6516013 0.82 CA2 (0.36) POLBKMT2ATSHRRXFP1MEN1
SCHEMBL6040594 0.81 TNFRSF1A (0.39) HPGDL3MBTL1KMT2ARXFP1MEN1
SCHEMBL6040478 0.81 CA2 (0.40) CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US claimed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US claimed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO claimed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 HPGD 845/4885POLB 4214/4885L3MBTL1 4861/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 HPGD 845/4885POLB 4214/4885L3MBTL1 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.